Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) EBIT Margin (2020 - 2025)

Neuroone Medical Technologies' EBIT Margin history spans 12 years, with the latest figure at 59.02% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 11129.0% year-over-year to 59.02%; the TTM value through Dec 2025 reached 87.71%, up 3031.0%, while the annual FY2025 figure was 46.46%, 29780.0% up from the prior year.
  • EBIT Margin reached 59.02% in Q4 2025 per NMTC's latest filing, down from 50.02% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 52.26% in Q4 2024 to a low of 13134.27% in Q1 2021.
  • Average EBIT Margin over 5 years is 2954.78%, with a median of 653.59% recorded in 2023.
  • Peak YoY movement for EBIT Margin: crashed -532557bps in 2021, then skyrocketed 805902bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 8324.42% in 2021, then skyrocketed by 81bps to 1557.31% in 2022, then skyrocketed by 78bps to 346.8% in 2023, then surged by 115bps to 52.26% in 2024, then crashed by -213bps to 59.02% in 2025.
  • Per Business Quant, the three most recent readings for NMTC's EBIT Margin are 59.02% (Q4 2025), 50.02% (Q3 2025), and 111.23% (Q2 2025).